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ABSTRACT Objective: Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to
select  which  drug  to  use  in  combination  with  radiotherapy.  Our  aim  was  to  identify  drugs  that  radiosensitise  CRC  cells  with
known BRAF status.
Methods: We screened 298 oncological drugs with and without ionising radiation in colorectal cancer cells isogenic for BRAF. Hits
from rank product  analysis  were validated in a  16-cell  line panel  of  human CRC cell  lines,  using clonogenic survival  assays  and
xenograft models in vivo.
Results: Most consistently identified hits were drugs targeting cell growth/proliferation or DNA damage repair. The most effective
class of drugs that radiosensitised wild-type and mutant cell lines was PARP inhibitors. In clonogenic survival assays, talazoparib
produced  a  radiation  enhancement  ratio  of  1.9  in  DLD1  (BRAF-wildtype)  cells  and  1.8  in  RKO  (BRAF V600E)  cells.  In  DLD1
xenografts, talazoparib significantly increased the inhibitory effect of radiation on tumour growth (P ≤ 0.01).
Conclusions: Our  method  for  screening  large  drug  libraries  for  radiosensitisation  has  identified  PARP  inhibitors  as  promising
radiosensitisers of colorectal cancer cells with wild-type and mutant BRAF backgrounds.
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Introduction
Colorectal  cancer  (CRC) is  one  of  the  most  common forms
of  cancer,  accounting  for  approximately  1  in  10  new cancer
diagnoses  worldwide  in  20121.  Radiotherapy  is  commonly
used  to  treat  rectal  cancers  prior  to  surgery  or  to  treat
inoperable  colorectal  metastases,  in  the  form  of  stereotactic
body radiotherapy or selective internal radiotherapy2-4.
International  standard  combination  therapy  for  rectal
cancer, radiotherapy delivered with 5-fluorouracil (5FU) as a
radiosensitiser, is given either as an infusion or as an oral
prodrug (capecitabine). There is currently no molecular basis
for  the selection of  patients  for  radiotherapy,  nor for  the
selection of any alternative drug to use as a radiosensitiser.
With  the  current  standard,  sufficient  downsizing  by
chemoradiotherapy  is  obtained  by  approximately  half  of
patients  treated5.  There  is  scope  for  improving  the
radiotherapy  approaches  currently  offered  to  patients.
Clinical  trials  have  added  additional  drugs  to  5FU  as  a
combination radiosensitising approach6,7 without molecular
selection, but these trials have not changed the international
standard.
Colorectal  tumours  have  a  heterogeneous  molecular
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background8. Commonly occurring CRC mutations that may
be  prognostic  or  can  affect  treatment  decisions  include
KRAS,  BRAF  and PIK3CA  mutations,  which are found in
42%,  9%  and  13%  of  CRC  patients  respectively9.  KRAS,
BRAF and PIK3CA are vital components of two main cellular
signalling pathways; RAS/MEK/ERK and PI3K/AKT/mTOR;
strongly inter-connected pathways that play central roles in
tumorigenesis  by  regulating  cell  survival,  proliferation,
metabolism, and motility. The KRAS gene is a member of the
oncogenic  RAS  gene  family  and binds  to  effector  kinases
including BRAF and phosphatidylinositol 3-kinase (PI3K).
The PIK3CA gene encodes the PI3K p110α subunit, which
interacts with RAS proteins10.
The commonest BRAF mutation in colorectal cancer, the
V600E  substitution,  results  in  elevated  kinase  activity
a n d  c o n s t i t u t i v e  d o w n s t r e a m  M E K  a n d  E R K
phosphorylation11,12.  The  presence  of  BRAF  V600E  in
advanced CRC correlates with poor prognosis with markedly
worse progression after chemotherapy13-15. BRAF mutation is
predictive of poor response to cetuximab in metastatic CRC,
also  observed  for  KRAS  and  PIK3CA  mutations16-18.
Although patients with BRAF-mutant cancers do less well
with chemotherapy, anti-EGFR therapies and surgery19, there
is  currently  no  suggestion  that  they  benefit  less  from
radiotherapy. Although BRAF mutation is relatively rare in
rectal  cancer,  radiotherapy  can  also  be  used  to  treat
inoperable liver metastases from CRC. It has been suggested
that CRC liver metastases respond less well to radiotherapy
than liver  metastases  from other  primary  malignancies20,
hence the addition of a radiosensitising drug may be of value
to improve the therapeutic index during radiotherapy21.
Our aim was to develop a radiosensitiser drug discovery
assay  enabling  identification  of  drugs  that  will  enhance
radiotherapy  more  effectively  than  the  current  standard,
5FU,  and  demonstrate  activity  in  defined  molecular
backgrounds. Firstly, we developed a high throughput screen
(HTS),  in  CRC cell  lines,  to  identify  drugs  that  could  be
effective  radiosensitisers  in  the  context  of  BRAF  V600E
activating mutations. The drugs identified during the screen
were validated across an extensive panel of human CRC cell
lines, selected to represent aspects of the molecular landscape
of  CRC;  including  BRAF  V600E  in  both  MSI  and  MSS
backgrounds,  and a  spectrum of  KRAS,  PIK3CA  and p53
mutations.  Such cell  line panels  recapitulate the different
subtypes  found  in  CRC,  are  representative  of  genetic
alterations found in primary cancers and are good predictors
of clinical efficacy during drug development programmes22.
Here,  we  use  this  model  to  test  new  drug-radiotherapy
combinations for the first time, identifying PARP inhibitors
as the most strongly radiosensitising class of agent before
validating by clonogenic survival assays and in vivo xenograft
studies.
Materials and methods
Cell lines, drug library and irradiations
The parental  CRC cell  lines RKO (BRAF V600E/V600E/WT)
and  VACO432  (V600E/WT)  and  their  isogenic  pairs  RKO-
T29 (BRAF WT/-/-) and VACO432-VT1 (BRAF WT/-) were
a  gift  from  Sandra  Van  Schaeybroeck,  Queens  University,
Belfast,  UK (mutation status confirmed by sequencing). The
panel  of  colorectal  cancer  cell  lines  utilised  for  cell
proliferation assays was obtained from Prof. Walter Bodmer,
University  of  Oxford,  UK.  The  cell  line  panel  is  listed  in
Supplementary  Table  S1,  and  has  been  previously
described22.  Non-malignant  cell  lines  were  obtained  from
Prof.  Gillies  McKenna,  University  of  Oxford,  UK.  All  cell
lines  were  used  within  12  passages,  or  where  necessary,
replenished  using  frozen  aliquots  of  the  initial  passage.
Isogenic  cell  lines  were  grown  in  McCoy's  5A  (Modified)
Medium, and other cell lines in DMEM; both supplemented
with 10% Fetal Bovine Serum and 1 × penicillin/streptomycin
(Thermofisher Scientific Inc., MA, USA), in a 37°C, 5% CO2,
humidified incubator. The small compound anti-cancer drug
library  was  provided  in  384-well  plate  format  (Target
Discovery  Institute,  University  of  Oxford),  and  contained
222  drugs  from  the  TDI  Extended  Oncology  Drugs  Library
(ODL)  and  76  from  the  NCI  Developmental  Therapeutics
Program  (DTP)  Approved  Oncology  Drug  set
(Supplementary Table S2).
A GSR D1 irradiator  (Gamma-Service  Medical  GmbH,
Leipzig, Germany) a Cs-137 source, (dose rate 1.5 Gy/min)
was used for cell irradiations. For xenografts, a RS320 X-ray
irradiator  (Gulmay  Limited,  Byfleet,  UK)  was  used  (1.6
Gy/min),  with  lead  shielding  to  localise  dose  to  tumor.
Dosimetry was calculated from optical density of scanned
Gafchromic EBT3 film (Ashland, NJ, USA), corrected and
calibrated to the National Physical Laboratory (Teddington,
UK) primary standard.
High-throughput drug screen with ionising
radiation
Methodology  and  data  analysis  followed  internationally
recognised  high-throughput  screening  guidelines23. BRAF
V600E isogenic  RKO  and  VACO432  cells  were  seeded  in
52 μ L/well  by  Flexdrop  (PerkinElmer,  MA,  USA).  Seeding
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density in 384-well plates was 300 cells/well (RKO) and 1,000
cells/well  (VACO432).  Eighteen  hours  after  seeding,  cells
were screened with 298 oncological drugs, in 5-fold dilutions
from 10 μM–16 nM. Janus  workstations  (PerkinElmer,  MA,
USA) were used to transfer 13 μL of compound from library
plate  to  cell  culture  plates.  Positive  controls  were  PI103 and
vorinostat,  negative  controls  were  vehicle  (DMSO)  alone.
After  6  h,  plates  were  either  mock-irradiated,  or  irradiated
with 4 Gy. Media was replaced 24 h following treatment, and
surviving  cells  allowed  to  proliferate  for  five  doubling  times
as  optimised  in  preliminary  screens.  Cell  viability  was
measured by  resazurin  (10  μ g/mL)  in  phenol  red-free
DMEM.  Metabolically  viable  cells  reduce  resazurin  to
fluorescent  resorufin,  which  was  quantified  by  PerkinElmer
Envision  microplate  reader  (540  nm  excitation/590  nm
emission).  Control  wells  reached  90%–100%  confluency  at
the  time of  assay  performance,  control  irradiated wells  were
around  60%  confluent.  Raw  data  were  normalized  by
rescaling  to  plate  mean  intensity  and  to  negative  controls.
Quality  plots  were  contrasted  to  assess  artifacts  and
reproducibility.  Normalized  data  Z  are  presented,  as  the
applied  rescaling  by  plate  mean  is  effectively  a  z-score
standardization.  Selection  of  candidate  hits  was  based  on
rank  product  analysis,  adapting  a  published  method24.
Specifically,  for  each  pair  of  conditions  (i.e.  with/without
irradiation),  the  differences  between  normalised  screen
intensities  were  calculated  for  each  well,  hence  each  drug.
These differences are presented as Delta-Z (ΔZ) scores. Rank
product  applied  to  these  differences  identified  compounds
producing  large  and  consistent  changes.  Probability  of  false
discovery  was  computed  by  permutation,  with n  =  100.
Analyses  were  implemented  in  R  version  2.1  (https://cran.r-
project.org/);  heatmaps  were  generated  by  modifying  D3.js
libraries (https://d3js.org/).
Cell proliferation and colony formation assays
Our  method  for  comparison  of  IC50 in  the  presence  or
absence  of  radiation  has  been  described  previously25.
Clonogenic  survival  was  measured  following  a  standard
method,  with  plating  efficiency  and  surviving  fractions
calculated as described26. Briefly, cells were seeded into 10 cm
culture  dishes,  normally  500  cells/plate  (for  0  Gy  plates),
increasing by 10-fold for each 4 Gy administered, to 500,000
cells/plate  (12  Gy).  After  attachment  (overnight),  cells  were
drug-treated, and six hours later exposed to 0, 4, 8 or 12 Gy
radiation.  Culture  medium  was  replaced  24  hours  post-
irradiation,  plates  were  incubated to  form visible  colonies  >
50 cells (10 – 15 days) and fixed with 0.4% methylene blue in
methanol. Survival curves were fitted using Graphpad Prism
v7.0A.  Radiation  enhancement  ratio  (RER)  was  obtained
from  the  ratio  of  radiation  dose  at  1%  survival  of  vehicle
compared with drug treated cells.
Xenograft studies
Animal  experiments  were  performed  following  local  ethical
review under licence from the UK Home Office (ASPA 1986,
revised January  2013).  Female  Balb/c  nude mice  (6–8 weeks
old)  were  anaesthetised  with  2%  isoflurane  and
subcutaneously injected with 50% matrigel containing 5x106
DLD1  cells  or  5  ×  106 RKO/mouse  (n =  24)  into  the  back.
When tumor volume reached 100 mm3, mice were randomly
placed into 4 groups (n = 6/group). Oral treatments were by
gavage,  in  two  doses  on  the  first  and  fourth  days  of
treatment.  Group  (1)  received  vehicle  only,  10%
dimethylacetamide/6%  solutol  HS/PBS  (0.1mL/10  g  body
weight). Group (2) received talazoparib; 0.1 mg/kg in vehicle.
Radiation  treatments  comprised  2  ×  5  Gy,  localised  to  the
tumor, also on the first and fourth days of treatment. Group
(3) received radiation only, 5 Gy one hour after each vehicle
treatment.  Group (4)  received combination treatment,  5  Gy
one  hour  after  each  talazoparib  treatment.  Tumor  size  was
measured by caliper 3 × per week. Mice were sacrificed when
tumours  reached  400  mm3 or  42  days  following  the  first
treatment.  Tumours were formalin fixed and stained for the
hypoxia marker CA9 as previously described27.
Results
Development of a high throughput screen with
ionising radiation
In  order  to  identify  drugs  that  radiosensitise  CRC  cells
mutated  for  BRAF  V600E,  isogenic  cell  lines  containing
either  BRAF  V600E  or  BRAF  WT  variants  were  screened
against  a  298-compound  library  of  approved  anticancer
drugs. Mutation status for KRAS, PIK3CA and p53 for these
cell  lines  is  shown  in Figure  1A,  with  the  screen  protocol
outlined in Figure 1B.
A  prerequisite  for  high-throughput  detection  of
radiosensitisers is an assay that is predictive of the effects of
drug/ radiation combinations on clonogenic cell  survival.
Extended  incubation  following  irradiation  improves
correlation with radiosensitisation28, and we incorporated 5
days incubation following radiation treatment; improving
correlation to clonogenic survival, but avoiding compromises
to  cell  metabolism  and  thus  assay  performance29.  Serial
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dilution  of  cells  in  the  presence  of  resazurin  showed
equivalent fluorescence, linear in relation to cell number, for
both non-irradiated cells, and cells 5 days post-irradiation
(data not shown). This indicates that the metabolic assay was
a good surrogate for cell number at this timepoint.
Screens were carried out  in duplicate  and quality  plots
demonstrated good reproducibility (Figure 1C), with mean
Pearson correlation between pairs of replicates of 0.88 and
average  Z  factor  of  0.58  for  irradiated  and 0.53  for  non-
irradiated  plates.  Cell  viability  was  compared  between
normalized irradiated and non-irradiated plates, generating
heatmaps  of  the  difference,  ΔZ,  for  each  compound.  Hit
selection (Figure 1D) was based on rank product analysis,
with  the  probability  of  false  discovery  computed  by
permutations (see Materials  and methods).  Potential  hits
were drugs that sensitised the BRAF-mutant isogenic variant,
at  one  or  more  concentrations,  with  probability  of  false
positive (PFP) ≤  0.05.  Some plates  showed a pronounced
‘edge  effect’,  and  for  this  reason,  analysis  was  repeated
considering the edge wells as a separate population (Figure
1E). Hits with significant ΔZ score between irradiated and
non-irradiated samples, with radiosensitisation factor < 1
(normalised against control plates) and P-value ≤ 0.05 were
selected as significant.  Positive controls  were consistently
identified as hits, with ΔZ scores ≤ 2, comparable to results
obtained in manual assays.
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Figure 1   High-throughput screening of FDA approved cancer drugs to identify which drugs should be used for radiosensitisation in the
context of single gene mutations in colorectal cancer. (A, B) CRC cells isogenic for BRAF V600E and with defined KRAS, PIK3CA and p53
status were screened with the DTP approved oncology drug library +/- irradiation and allowed to grow for five doubling times. Cell viability
was compared between irradiated and non-irradiated plates. (C) Raw data were normalized by rescaling both to the plate mean and
negative controls, and quality plots contrasted. (D) Heatmaps were generated for each individual plate. ΔZ scores were calculated between
irradiated and non-irradiated plates. Selection of candidate hits was based on a rank product method (see methods). Probability of false
discovery was computed by permutation, with 100 permutations. (E) Example heatmap generated for one of the HTS plates. Hits were
identified as drugs with a ΔZ score significantly higher than expected by chance when irradiated and non-irradiated samples were
compared.
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BRAF V600E screen in isogenic cell lines
following irradiation
Drugs  were  ranked  according  to  radiosensitisation  against
BRAF-mutated  cells.  The  fifteen  drugs  with  the  highest
significance against BRAF-mutated cells are shown in Table 1.
Seven hits have previously been identified as radiosensitisers
in  the  published  literature30-36,  helping  to  validate  our
methodology.  Five  hits  were  inhibitors  of  RAS/RAF/
MEK/ERK  pathway  (trametinib,  TAK-733,  pimasertib,
doramapoimod  and  dactolisib),  predominantly  acting  in
BRAF WT and V600E. Eight drugs reached significance in the
BRAF-mutant  cell  line  but  not  in BRAF  WT,  including  the
CHK1  inhibitor,  PF477736.  Another  CHK1  inhibitor,
AZD7762, radiosensitised both BRAF variants.
The  poly(ADP-ribose)  polymerase  (PARP)  inhibitor,
olaparib, significantly increased sensitivity to irradiation in
BRAF  V600E  RKO  cells.  In  a  separate  screen  of  BRAF
isogenic Vaco432 cells, olaparib also radiosensitised BRAF
V600E Vaco432 cells at 16 nM and 80 nM (P ≤ 0.05, data not
shown).  Based on these  data,  radiosensitisation by PARP
inhibitors (PARPi) in RKO isogenic for V600E and WT, was
validated  by  long-term  proliferation  assay  at  a  broad
concentration range and by clonogenic cell  survival  assay
(Figure  2).  Olaparib  as  a  single  agent  had little  effect  on
survival,  but  combination  treatment  caused  a  significant
increase in radiation sensitivity, albeit with similar effect in
both BRAF WT and V600E variants.
Radiosensitisation in an extended CRC cell
line panel
To validate  the  screen,  we  used a  cell  line  panel  inclusive  of
the  different  molecular  subtypes  of  CRC.  We  specifically
prioritised  the  drug  hits  with  the  most  immediate  scope  for
translation  to  clinical  trials  in  combination  with
radiotherapy.  The cell  line panel  was  selected so that  several
cell lines exhibited each gene mutation of interest. Fifteen cell
lines with defined BRAF,  p53,  KRAS,  PIK3CA  and mismatch
repair  status  were  used.  The  compounds  chosen  for  further
testing are  shown in Table  2,  along with p-values  indicating
whether  significant  IC50 shift  was  observed  following
normalisation for radiation effect.  The complete IC50 results
determined  by  these  assays  are  shown  in Supplementary
Table S3.
From these assays, olaparib and rucaparib displayed potent
Table 1   Fifteen radiosensitisers identified for BRAF-mutant cells
Compound Effective concentrationin RKO (BRAF mut) (μM)
Effective concentration
in RKO (BRAF WT) (μM) Mechanism of action
Dactolisib 0.016, 0.4 0.016 Dual PI3K/mTOR inhibitor
Panobinastat 0.016 ns HDAC inhibitor
Trametinib 0.016 0.016 MEK inhibitor
ABT-199 0.08 0.08 Bcl-2 inhibitor
Olaparib 0.08 ns PARP inhibitor
Tosedostat 0.08 ns Peptidase inhibitor
AZD 7762 0.08 0.08 Chk inhibitor
Pimasertib 0.4, 0.08 0.08 MEK inhibitor
PF477736 0.08 ns Chk1 inhibitor
17-AAG 0.08 ns Hsp90 inhibitor
Doramapimod 0.08 ns p38 MAPK inhibitor
Danusertib 0.08 ns aurora kinase inhibitor
Serdametan 0.4 0.4 MDM2 inhibitor
Tak-733 0.4 0.4 MEK inhibitor
Auranofin 0.4 ns Gold complex
RKO colorectal cancer cells BRAF V600E or WT were screened with 298 approved oncology drugs alone or in combination with irradiation.
Radiosensitisation factors were calculated from the ratio of fluorescence of irradiated versus non-irradiated plates. The most significant
hits for BRAF-mutant variant RKO cells are shown; each hit has radiosensitisation factor < 1, PFP ≤0.05 and P-values ≤0.05; ‘ns’ indicates
that significance was not reached in the BRAF WT cell line for the drug tested.
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radiosensitising ability across multiple cell lines. IC50 curves
(normalised for radiation effect) were significantly different
(P ≤ 0.01) for all except three cell lines; namely, C10, CW2
and Colo678 (Table 2).
Both Chk1 inhibitors, and trametinib, were also effective
radiosensitisers  in  the  majority  of  cell  lines  tested.
Vemurafenib was ineffective in BRAF WT (IC50 frequently
not reached), but showed some efficacy in BRAF mutated cell
lines,  (not significant for radiosensitisation). This limited
effect may arise from feedback activation of EGFR, PI3K or
alternative signaling pathways, reducing vemurafenib efficacy
in CRC when compared to melanoma37.
Validation of radiosensitisation by PARP
inhibitors with clonogenic survival assays
As PARPi were the most effective radiosensitisers of the CRC
cell  line  panel,  clonogenic  survival  assays  were  used  to
measure radiation enhancement ratios  (RERs) in 3 cell  lines
that were strongly radiosensitised (> 10-fold IC50 shift) and 3
cell  lines  with  IC50 shift  <  10-fold.  To  potentially  improve
PARPi  radiosensitisation  of  these  resistant  cell  lines,  a  more
trapping  PARPi,  talazoparib,  was  included  in  these  assays.
Survival  curves (Figure 3),  and RERs (Table 3) reflected the
proliferation  assay  results:  Olaparib  and  rucaparib
significantly  radiosensitised  RKO,  DLD1,  and  HT29
compared to vehicle-treated cells,  while radiosensitisation of
HT55,  Colo678,  and  C10  was  limited  –  although  significant
for  HT55  cells  treated  with  rucaparib.  Talazoparib
significantly  radiosensitised  all  cell  lines  tested,  and  was
overall  the  most  effective  radiosensitiser  (average  RERs
1.21–1.92),  followed  by  rucaparib  (average  RERs  1.15–1.41)
and finally olaparib (average RERs 1.12–1.4).
To  indicate  potential  normal  tissue  toxicity,  PARPi
experiments were repeated in three non-malignant cell lines,
HFLA, MRC5 and RPE. In clonogenic assays (Table 3), these
non-malignant  cells  were  significantly  radiosensitised  by
talazoparib. Radiosensitisation by rucaparib was significant
for HFLA and MRC5, and radiosensitisation by olaparib was
significant only for MRC5 cells (P ≤ 0.05).
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Figure  2     Validation  of  radiosensitisation  effects  of  olaparib  in  BRAF-mutant  and  BRAF-WT isogenic  CRC cells.  Confirmation  of
radiosensitisation by olaparib in BRAF mutant and WT RKO cells by: (A) Long-term cell proliferation assays, showing separation (red arrows)
between IC50 curves normalised for radiation effect, indicating significant radiosensitisation (BRAF-mutant: P ≤ 0.001; BRAF-WT: P ≤ 0.01,
calculated by paired t-test). (B) Clonogenic survival assays, showing significant radiation enhancement by 0.1–1 μM olaparib at 1% cell
survival (BRAF-mutant: P ≤ 0.05; BRAF-WT: P ≤ 0.001), calculated by one-way ANOVA in multiple comparison tests). Data show the mean of
n = 3 experiments ± SEM (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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Validation of PARP inhibitors as
radiosensitisers in xenograft studies
The  PARP  inhibitor  talazoparib  was  the  most  effective
radiosensitiser  and  had  not  previously  been  tested  with
radiotherapy in animal CRC models. To confirm the in vitro
radiosensitisation by PARPi in an in vivo model,  talazoparib
was  tested  against  two  cell  lines  that  were  effectively
radiosensitised  by  the  drug  in  2D  assays.  Mice  were
inoculated  with  subcutaneous  tumors  consisting  of  RKO  or
DLD1  cells,  and  treated  with  talazoparib  or  vehicle,  either
alone  or  one  hour  before  each  of  2  ×  5  Gy  radiation
treatments. In DLD1 cells (Figure 4A), single treatment with
talazoparib or radiation alone did not inhibit tumour growth.
Combined  talazoparib/radiation  treatment  was  tolerated  by
the mice, and significantly reduced tumour growth compared
with  radiation  alone  (P ≤  0.01).  For  the  RKO cell  xenograft
model, there was no significant difference between the effect
of  radiation  alone,  and  the  radiation/talazoparib
combination.  Tumour  histology,  levels  of  perinecrotic
hypoxia  (CA9  staining)  and  necrosis  were  similar  for  both
cell types (Figure 4B).
Discussion
The  aim  of  this  study  was  to  identify  treatment  options  to
radiosensitise  colorectal  cancer  cells  in  the  context  of  key
mutations  that  characterise  the  disease.  Biopsies  from  CRC
patients are routinely screened for BRAF, KRAS and PIK3CA
mutations,  but  this  information  is  not  currently  used  in
treatment  decisions  regarding  radiotherapy.  There  is
preclinical evidence that single gene alterations in cancer can
determine  the  extent  of  radiosensitisation  exerted  by
different  drugs.  Examples  include  mammalian  AMP-
activated  protein  kinase  dependence  of  pancreatic  cancer
cells  to  radiosensitisation  by  metformin38,  the  role  of
mismatch  repair  deficiency  in  radiosensitisation  of  CRC
cell  lines  by  gemcitabine39-40 and  p53-dependent
radiosensitisation by valproic  acid41.  Radiosensitisation drug
discovery across different genetic  backgrounds may enable a
A
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Figure 3   Clonogenic assays to confirm radiosensitisation of multiple cell lines by PARP inhibitors. (A) Colorectal cancer cell lines were
plated, rested overnight, drugged and 6 hours later, the cells were either mock irradiated, or irradiated at 4, 8, or 12 Gy. Separation between
the control (DMSO) and treated curves indicates radiosensitivity induced by the compound. (B) Human lung fibroblast (HFLA and MRC5)
and retinal epithelial (RPE) non-malignant cell lines were drugged in an identical manner and irradiated with 0, 4 or 8 Gy to determine non-
cancer cell survival following similar treatment. Data show mean of n=3 experiments±SEM.
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change from a “one size fits all” chemo- radiotherapy to the
identification of the most appropriate drugs for radiotherapy
based on the genetic profile of the cancer.
To address our primary aim, we developed a novel high-
throughput  screen  to  test  drug  library/radiotherapy
combination against cell lines. For drug repurposing, which
allows  more  rapid  translation  in  to  the  clinic,  we  used  a
library of drugs already in clinical  use or in clinical  trials.
Previous investigators using more focused library screens
have successfully identified radiosensitisers of CRC42 and our
study  identified  the  same  drugs  with  radiosensitising
potential,  the  CHK  inhibitor,  AZD-7762,  and  the  dual
mTOR/PI3K inhibitor, dactosilib. We initially used isogenic
cell lines to identify radiosensitisers active in a BRAF V600E
background.  Reassuringly,  our  results  confirmed
radiosensitisation by  agents  from drug classes  previously
shown to have radiosensitising activity in other published
papers,  such  as  inhibitors  of  the  RAS/MEK/ERK,  and
PI3K/MTOR  pathways.  In  addition,  we  identified
compounds  not  previously  known  to  be  radiosensitisers
(Table  1).  Of  the  drugs  targeting  mutated  BRAF
(vemurafenib,  dabrafenib,  RAF265),  only  vemurafenib
reached the threshold for hit-detection in the screen, possibly
because vemurafenib is a more potent radiosensitizer, at least
compared with dabrafenib43.
Cell  lines  manipulated by  gene mutation might  not  be
entirely representative of the molecular landscape of cancer
in patients. We therefore validated results from isogenic cell
lines  in  a  panel  of  human  colorectal  cancer  cell  lines,
inclusive of common CRC mutations and previously shown
to  be  a  useful  model  for  drug  development22,44.  This
approach was also novel  since this  cell  line panel  has  not
previously  been  used  to  test  new  drug-radiotherapy
combinations.  The results (shown in Table 2),  confirmed
PARPi as significant radiosensitisers, notably across a much
broader  range  of  cell  lines  than 5FU,  the  current  clinical
standard,  suggesting  that  5FU  may  not  be  the  optimal
treatment for all CRC patients compared to newer and more
targeted drugs. This reflects data in other studies in CRC,
which show that radiosensitisation by 5FU varies depending
on the cell  line used45,46.  Additionally,  the timing of  5FU
exposure may influence the degree of radiosensitisation47.
In  future,  immunotherapy  is  likely  to  be  of  increasing
importance in CRC treatment, although at present it is only
used to treat the more immunogenic MSI-high tumours48.
Despite this, radiotherapy is likely to remain an important
treatment  for  rectal  cancer  and  metastatic  disease,
particularly  when  the  cost  effectiveness  of  treatment  is
considered. The broad range of cell lines for which PARPi
appear  to  be  suitable  radiosensitisers  in  this  study  may
predict  its  potential  future  utility  in  a  wide  patient
population.
Three  PARPi,  olaparib,  rucaparib,  and niraparib,  have
been approved by the US FDA for the treatment of ovarian
cancer,  including  BRCA-deficient  tumours  that  have
deficient homologous recombination repair. PARPi function
Table 3   Radiation enhancement ratios of PARP inhibitors for colorectal cancer and non-malignant cell lines
Gene mutation status Radiation enhancement ratio (P-value)
BRAF KRAS PIK3CA p53 Olaparib Rucaparib Talazoparib
CRC cell lines
RKO p.V600E WT p.H1047R WT 1.48 (P ≤ 0.05) 1.41 (P ≤ 0.05) 1.71 (P ≤ 0.001)
HT29 p.V600E WT WT R273H 1.44 (P ≤ 0.01) 1.28 (P ≤ 0.001) 1.82 (P ≤ 0.001)
DLD1 WT G13D p.E545K S241F 1.18 (P ≤ 0.01) 1.21 (P ≤ 0.01) 1.92 (P ≤ 0.001)
HT55 WT WT WT R213L 1.21 (ns) 1.31 (P ≤ 0.01) 1.39 (P ≤ 0.01)
C10 WT WT WT G245S 1.12 (ns) 1.18 (ns) 1.48 (P ≤ 0.001)
Colo678 WT G12D WT WT 1.12 (ns) 1.15 (ns) 1.21 (P ≤ 0.001)
Non-malignant cell lines
HFLA n/a n/a n/a n/a 1.09 (ns) 1.3 (P ≤ 0.05) 1.29 (ns)
MRC5 n/a n/a n/a n/a 1.35 (P ≤ 0.05) 1.34 (P ≤ 0.05) 1.52 (P ≤ 0.01)
RPE n/a n/a n/a n/a 1.1 (ns) 1.07 (ns) 1.24 (P ≤ 0.01)
Radiation enhancement ratios were calculated from clonogenic survival assays (normalised, by plating efficiency, for effect of drug alone)
and comprise the ratio of radiation dose leading to 1% cell  survival to the radiation dose producing 1% survival in the combined
treatment. Significance (P ≤ 0.05), displayed by in bold, was calculated by one-way ANOVA, with multiple comparisons of each drug
against the DMSO control.
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by inhibiting the binding, or enzymatic activity, of PARP to
single strand breaks in DNA. The absence of SSB repair leads
to double strand break (DSB) formation at the approaching
replication fork, and cell death. It has been shown that PARPi
have  an  increased  radiosensitising  effect  on  DSB-  repair
deficient tumour cells compared with DSB- repair proficient
lines49. Compared to olaparib and rucaparib, we found that
talazoparib treatment led to higher RERs. PARPi affect cell
proliferation  by  two  main  actions:  inhibiting  PARP
enzymatic function, and by binding (‘trapping’) PARP to
DNA50. Olaparib and rucaparib function primarily through
inhibiting enzymatic function, whereas talazoparib ‘traps’
PARP at DNA damage sites, with increased anti-proliferative
effect ,  potential ly  contributing  to  more  effective
radiosensitisation51,52.
We  proceeded  to  show  that  the  PARP  inhibitor,
talazoparib,  radiosensitised DLD1 xenografts  in vivo.  The
combined  treatment  caused  a  prolonged  tumour  growth
delay,  in excess  of  the effects  demonstrated elsewhere for
combined  5FU/radiation  treatment  for  HCT11645  and
WiDr53 CRC xenografts. It is unclear why talazoparib did not
significantly radiosensitise BRAF mutated RKO xenografts in
vivo. It has been shown that BRAF-mutant early neoplastic
lesions have upregulation of gene sets involved in aberrant
DNA methylation54 and that BRAF-mutant cancers can have
distinct tumour-associated-stroma and components of the
extracellular  matrix  that  are  different  from  wild-type
cancers55. These complexities may explain the discrepancy
between  the  highly  significant  results  we  obtained  in  2D
culture and the non-significant results we obtained in vivo
using the same cell line. Future studies should consider the
use of other models, such as patient-derived xenografts or
immunocompetent  mouse  models,  to  explore  this
discrepancy further.
Some investigators  advocate  preclinical  comparison of
non-malignant with malignant cell lines to identify cancer-
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Figure 4   Talazoparib significantly enhances the response of colorectal cancer cells grown in vivo to ionizing radiation. (A, B) Growth of
tumour cells injected subcutaneously into the back of BALB/c nude mice, treated as indicated with either; vehicle; 0.1 mg/kg talazoparib;
radiation (2 x 5 Gy); or 0.1 mg/kg talazoparib 1 hour prior to each of 2 x 5 Gy radiation doses. Treatment with talazoparib+radiation
significantly slowed tumor growth for (A) DLD1 cells but not (B) RKO cells. (C, D) Representative images of tumours harvested from the
vehicle treated group (at 400 mm3) show similar histology for both (C) DLD1 and (D) RKO xenografts including perinecrotic hypoxia (CA9
staining, brown) and tumor necrosis (N).
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specific  drugs56,57.  In  our  study,  olaparib  did  not  cause
significant radiosensitisation of two non-malignant cell lines,
HLA and RPE. An in vivo study of intestinal crypt damage, in
which  fractionated  radiotherapy  was  combined  with
olaparib,  did  not  appear  to  cause  additional  gut  toxicity
compared to  radiotherapy without  drug58.  Contrastingly,
clinical studies of PARPi have documented bowel toxicities as
side effects of treatment59 and total body irradiation of a p21-
reporter mouse has shown that olaparib can exacerbate DNA
damage in normal tissues when combined with radiation60. It
should be noted that, in our study, rucaparib and talazoparib
caused significant radiosensitisation of 2 non-malignant cells
tested by clonogenic survival assays. Although talazoparib has
already completed phase I development as a single agent61,
we  recommend  that  the  normal  tissue  toxicity  from  the
combination of PARPi with radiotherapy should be assessed
further  in  preclinical  normal  tissue  toxicity  models  and
monitored closely in early-phase clinical trials.
In conclusion, our novel approach to radiosensitisation
drug  discovery  in  cells  isogenic  for  the  BRAF  V600E
mutation,  has  led  to  the  identification  of  PARPi  as
radiosensitisers  for  CRC.  Validation  in  a  broad  panel  of
human CRC cell lines, and an in vivo xenograft model, has
shown potentially broader radiosensitising activity than the
current  clinical  standard of  care,  5FU.  Following toxicity
evaluation of the combination of PARPi with radiotherapy in
other preclinical models, we propose that PARP inhibition
should be tested in combination with radiotherapy for rectal
cancer or metastatic CRC treatment, with careful monitoring
of potential toxicities.
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Table S2   Anticancer drugs comprising the small compound library for the screen
(5Z)-7-Oxozeaenol Bleomycin FK 506_Tacrolimus Mitomycin C Rapamycin (sirolimus)
(R)-Flurbiprofen (Tarenflurbil) BMS-754807 FK-866 HCl_Daporinad Mitotane RD162
1-methyl-D-tryptophan, 95% BMS-911543 Floxuridine Mitoxantrone RDEA119_Refametinib
17-AAG (Tanespimycin,
Geldanamycin)
Bortezomib Fludarabine MK-0752 Ridaforolimus
17-DMAG (Alvespimycin) Bosutinib Fluorouracil MK-2206 Rofecoxib (Vioxx)
2-methoxyestradiol (Panzem) Brivanib Flutamide MK-4827, HCl salt Romidepsin
4-hydroxytamoxifen Busulfan Fulvestrant MK1775 Roscovitine_Selicilib
Abitrexate/Methotrexate Cabazitaxel Galiellalactone MLN4924 S-trityl-L-cysteine, 40 mM
ABT-199 CAL-101 GDC-0068 MLN8237_Alisertib SB 743921
ABT-263 (Navitoclax) Camptothecin GDC-0941_Pictilisib Motesanib Di phosphate
(AMG-706)
Simvastatin
ABT-751 Canertinib GDC-0980 Nelarabine Sorafenib
ABT-869_Linifanib Capecitabine Gefitinib Nilotinib Sotrastaurin
ABT-888 (Veliparib) Carboplatin Gemcitabine HCl Nilutamide SR1 HCl
AC220_Quizartinib Carfilzomib Goserelin acetate Nitrogen mustard Stattic
Acrichine Carmustine GSK 269962 Nutlin-3 Streptozocin
Table of compounds tested from the combined TDI Extended Oncology Drugs Library (ODL) and the NCI Developmental Therapeutics
Program (DTP) Approved Oncology Drug Library.
Continued
Table S1   Details of the cell lines
Cell line BRAF KRAS PIK3CA P53 MSI/MSS CIMP
C10 WT WT WT WT MSS CIMP-
C99 WT WT WT WT MSS CIMP-
CCK81 WT WT C420R, C472Y P278H MSI CIMP-
COLO678 WT G12D WT WT MSS CIMP+
CW2 † WT P140H P283S WT MSI na.
DLD1 WT G13D E545K S241F MSI CIMP+
HCA7 WT WT WT P301fs*44 MSI CIMP+
HT29 V600E WT WT R273H MSS CIMP+
HT55 V600E WT WT .R213L MSS CIMP-
LS411 V600E WT WT Y126* MSI CIMP+
OXCO4 † V600E WT WT mutant MSS na.
RKO V600E WT H1047R WT MSI CIMP+
SW1222 WT A146V WT WT MSS CIMP-
SW403 WT G12V Q546K E51* MSS CIMP-
VACO5 † WT WT H1047R mutant MSI na.
Table of cell lines comprising the panel for screen validation: Data is from Mouradov et al., Cancer Res. 2014; 74: 3238-47, except where
indicated. † Indicates data from Prof. Walter Bodmer, personal communication. na. Indicates information not available
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AG-014699_Rucaparib Celecoxib GSK 650394 NVP-AUY922 Sunitinib
Allopurinol CHIR-258 (Dovitinib) GSK1120212_ Trametinib NVP-BEZ235_Dactolisib TAK-733
Altretamine Chlorambucil GSK2126458 NVP-BGJ398 TAK-901
Amifostine Chloroquine
diphosphate
GSK2636771 NVP-LDE225
(Diphosphate salt)
Tamoxifen citrate
Aminoglutethimide CHR
2797_Tosedostat
HA-1077 (Fasudil) Obatoclax Mesylate
(GX15-070)
Tandutinib
Aminolevulinic acid CI-994_Tacedinaline Homoharringtonine Olaparib Tasocitinib_Tofacitinib
Amonafide Cisplatin aq Hydroxyurea OSI-027 Temozolomide
Anagrelide Cladribine I-BET151 (GSK1210151A) OSI-906_Linsitinib Teniposide
Anastrozole Clafen (Cyclophos-
phamide, Endoxan)
Idarubicin HCl Oxaliplatin Tetramisole HCl
AP24534 (Ponatinib) Clofarabine Ifosfamide PAC-1 TGX-221
ARQ 197_Tivantinib Clomifene citrate Imatinib Paclitaxel Thalidomide
ARRY-162_MEK-162 CPI-613 Imiquimod Panobinostat Thio-TEPA
Arsenic(III) oxide Crenolanib INCB018424 (free base,
Ruxolitinib)
Pazopanib Thioguanine
AS703026_Pimasertib Crizotinib Indibulin PCI-32765_Ibrutinib Thiotepa
Aspirin (Acetylsalicylic Acid) CUDC-101 Iniparib (BSI-201, IND-
71677)
PD-0332991 Tipifarnib (Zarnestra)
AT 101 Cyclophosphamide INK128 Pemetrexed Topotecan HCl
AT-406 CYT-
387_Momelotinib
Irinotecan Pentostatin Toremifene citrate
AT9283 Cytarabine HCl Ixabepilone Perifosine aq/PBS Tretinoin
Atorvastatin Ca Dabrafenib Mesylate JNJ 26854165
(Serdemetan)
PF 431396 Triethylenemelamine
Auranofin Dacarbazine JNJ_26481585_Quisinostat PF 477736 Tubacin
AV-951 (Tivozanib) Dacomitinib
(monohydrate) (PF-
00299804)
KX2-391 PF-04691502 Tubastatin A HCl
AVN944 Dactinomycin Lapatinib, di-p-
toluenesulfonate salt
PF-04708671 UCN-01
Axitinib Dasatinib Lasofoxifene PF-2341066 (Crizotinib) Uracil mustard
AZ 3146 Daunorubicin HCl Lenalidomide PF-3845 Valproic acid
Azacitidine DCC-
2036_Rebastinib
Lestaurtinib PF4800567 hydrochloride Valrubicin
AZD 7762 hydrochloride Decitabine Letrozole PF670462 Vandetanib
AZD1152-HQPA Decitabine
(Dacogen)
Lomeguatrib PHA-739358 (Danusertib) Varespladib
AZD1480 Deferoxamine
mesylate
Lomustine, CCNU PIK-75 HCl Vatalanib
AZD2014 Dexamethasone
(Decadron)
LY 333531 mesylate-
Ruboxistaurin
Pilocarpine Vemurafenib
AZD4547 Dexrazoxone LY2157299 Pipobroman VER 155008
Continued
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AZD6244 (Selumetinib) Dinaciclib
(SCH727965)
LY2228820 (CP868569) PKC412_Midostaurin Vinblastine sulfate
AZD8055 Docetaxel LY2603618_Rabusertib Plerixafor Vincristine Sulfate
(Oncovin)
BAY 73-4506_Regorafenib Doxorubicin LY2784544_Gandotinib Plicamycin Vinorelbine tartrate
Belinostat (PXD101) Doxorubicin HCl Masitinib PLX4032_Vemurafenib Vismodegib
Bendamustine HCl EMD1214063 MDV3100_Enzaluamide Pralatrexate Vorinostat
Bexarotene Entinostat Megestrol acetate Pravastatin VX-11e
BI 2536 Enzastaurin Melphalan Prednisolone XAV-939
BI 6727_Volasertib Epothilone B
(Patupilone)
Mercaptopurine Prednisone XL-147
BIBF 1120_Nintedanib Erlotinib HCl Metformin
hydrochloride aq
Prima-1 Met XL184_Cabozantinib
BIBW2992 (Tovok)_Afatinib Estramustine sodium
phosphate
Methotrexate Procarbazine XL880 (Foretinib)
Bicalutamide Etoposide Methoxsalen PX-866_Sonolisib YM155
BIIB021 Everolimus Methylprednisolone Quinacrine HCl Zolendronic acid
Bimatoprost Exemestane MGCD-265 R406_Tamatinib ZSTK474
BIRB 796 (Doramapimod) FG-4592 MGCD0103_Mocetinostat RAF265
BKM-120_Buparlisib Finasteride Mithramycin A Raloxifene HCl
Table S3   IC50 (μM) for each drug at 0 and 4 Gy in a panel of colorectal cancer cell lines
Cell line 5-FU IC50 Vorinostat IC50 PI-103 IC50 Olaparib IC50 Rucaparib IC50 Mitoxantrone IC50
LS411 0 Gy 24.67
(17.58 to 35.46)
6.79
(3.99 to 11.91)
5.23
(3.47 to 8.12)
24.46
(15.71 to 38.89)
*62.18 16.75
(12.32 to 22.98)
LS411 4 Gy 21.95
(12.37 to 40.8)
14.55
(9.69 to 22.27)
2.76
(1.57 to 4.96)
2.11
(1.09 to 4.18)
1.72
(0.49 to 8.54)
7.8
(5.63 to 10.89)
VACO5 0 Gy 2.54
(1.95 to 3.35)
3.45
(2.47 to 4.9)
1.91
(1.05 to 3.58)
10.5
(3.83 to 29.59)
34.03
(21.2 to 58.03)
3.49
(0.87 to 14.64)
VACO5 4 Gy 0.99
(0.83 to 1.19)
3.37
(2.85 to 4)
0.48
(0.34 to 0.71)
0.75
(0.43 to 1.3)
3.07
(0.61 to 11.91)
1.24
(0.56 to 2.99)
RKO 0 Gy 2.51
(1.93 to 3.29)
6.51
(3.89 to 11.26)
1.55
(0.95 to 2.54)
8.63
(4.32 to 17.22)
61.23
(30.07 to 167.4)
9.75
(6.21 to 15.44)
RKO 4 Gy 1.15
(0.73 to 1.90)
2.14
(1.2 to 4.15)
0.33
(0.20 to 0.57)
0.35
(0.15 to 0.78)
0.3
(0.03 to 1.59)
2.9
(1.59 to 5.46)
HT29 0 Gy 9.12
(6.67 to 12.66)
3.47
(2.42 to 5.03)
* >20 17.93
(4.14 to 75.29)
51.82
(33.61 to 86.34)
6.58
(1.24 to 78.99)
HT29 4 Gy 6.6
(5.24 to 8.36)
4.18
(2.6 to 6.94)
* 12.94 2.21
(1.25 to 3.55)
5.48
(2.49 to 11.75)
3.06
(0.88 to 12)
OXCO4 0 Gy 16.71
(14.13 to 19.85)
6.09
(3.69 to 10.41)
2.42
(1.82 to 3.24)
26.88
(16.82 to 43.79)
13.11
(10.42 to 16.58)
0.89
(0.61 to 1.33)
OXCO4 4 Gy 9.45
(7.92 to 11.32)
3.82
(2.69 to 5.49)
1.13
(0.87 to 1.47)
6.07
(4.73 to 7.82)
2.5
(1.74 to 3.61)
0.59
(0.44 to 0.78)
IC50 was calculated using Graphpad Prism following normalisation for radiation effect, and is shown in μM, with 95% confidence limits in
parenthesis. * Where the curve shape did not allow calculation of IC50 in Graphpad, IC50 was calculated manually by interpolation. * >
indicates the highest concentration tested in cell lines where the IC50 was not reached.
Continued
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Cell line 5-FU IC50 Vorinostat IC50 PI-103 IC50 Olaparib IC50 Rucaparib IC50 Mitoxantrone IC50
CW2 0 Gy 20.19
(15.17 to 27.24)
4.49
(2.9 to 7.08)
4.97
(3.14 to 8.17)
17.05
(6.48 to 44.79)
36.91
(30.48 to 45.16)
19.81
(11.2 to 35.76)
CW2 4 Gy *20.1 5.33
(3.59 to 7.99)
4.21
(1.49 to 14.87)
* >20 * >30 21.02
(12.56 to 186)
DLD1 0 Gy 8.6
(6.77 to 10.99)
6.26
(3.07 to 13.72)
1.69
(0.94 to 3.08)
* >100 *30.41 4.08
(1.49 to 12.46)
DLD1 4 Gy 7.78
(5.26 to 11.81)
3.25
(2.02 to 5.42)
0.52
(0.29 to 0.95)
1.74
(0.89 to 3.5)
0.44
(0.15 to 2.1)
1.9
(1.33 to 2.72)
CCK81 0 Gy 29.85
(23.48 to 38)
10.4
(5.37 to 21.34)
1.27
(0.92 to 1.76)
>100 *48.51 *16.51
CCK81 4Gy 20.77
(16.64 to 26.01)
7.84
(4.13 to 15.86)
1.07
(0.81 to 1.44)
13.05
(7.62 to 22.53)
45.05
(11.83 to 105.1)
22.6
(11.62 to 60.7)
C10 0 Gy 43.38
(31.27 to 60.93)
2.05
(0.82 to 6.16)
0.98
(0.45 to 2.19)
* >100 23.7
(20.64 to 222.2)
3.92
(1.84 to 8.96)
C10 4 Gy 39.86
(17.15 to 101.3)
10.21
(1.3 to 74.5)
0.53
(0.27 to 1.17)
* >100 22.4
(6.87 to 130)
2.18
(1.14 to 4.29)
SW403 0 Gy 1.31
(0.86 to 2.02)
17.71
(7.57 to 49.28)
* >20 6.18
(1.46 to 26.89)
40.51
(27.91 to 61.56)
2.17
(0.94 to 5.27)
SW403 4 Gy 0.73
(0.49 to 1.09)
7.28
(4.53 to 12.05)
10.81
(5.35 to 27.22)
0.85
(0.28 to 2.46)
12.39
(5.71 to 26.75)
1.46
(0.66 to 3.41)
COLO678 0
Gy
85
(37.7 to 197.4)
8.68
(1.84 to 64.49)
2.3
(1.08 to 5.15)
* >200 * 48.67 5.96
(2.98 to 12.18)
COLO678 4
Gy
81.5
(70.58 to 129.3)
*5.5 2.24
(1.09 to 4.85)
* >200 * 45.79 20.31
(12.29 to 34.44)
SW1222 0 Gy 10.58
(5.80 to 20.42)
41.93
(16.03 to 134)
* >20 16.72
(9.97 to 28.91)
9.78
(4.56 to 22.31)
2.76
(1.63 to 4.8)
SW1222 4 Gy 3.23
(2.19 to 4.75)
4.07
(2.98 to 5.63)
0.75
(0.63 to 0.90)
0.42
(0.32 to 0.56)
* 0.32 0.73
(0.32 to 1.83)
HCA7 0 Gy 27.64
(22.63 to 33.87)
1.29
(0.93 to 1.80)
2.95
(1.71 to 5.26)
3.99
(3.16 to 5.05)
48.51
(35.36 to 68.98)
1.93
(0.57 to 6.89)
HCA7 4 Gy 19.82
(16.49 to 23.89)
0.82
(0.70 to 0.97)
1.14
(0.79 to 1.66)
0.24
(0.18 to 0.32)
0.36
(0.19 to 0.66)
0.75
(0.24 to 2.53)
HT55 0 Gy 10.53
(7.91 to 14.17)
2.11
(1.51 to 3)
2.87
(0.95 to 9.99)
41.07(4.96 to
28.01)
12.2
(8.31 to 18.19)
1.26
(0.86 to 1.85)
HT55 4 Gy 12.03
(8.91 to 16.48)
3.14(1.99 to 5.10) 2.58
(1.85 to 3.63)
7.88
(0.88 to 3.66)
1.47
(0.4 to 5.18)
1.27
(0.79 to 2.08)
C99 0 Gy 3.34
(2.11 to 5.72)
3.53
(1.8 to 7.46)
23.77
(8.94 to 31.98)
14.01
(4.11 to 53.54)
39.28
(21.29 to 81.87)
1.15
(0.58 to 2.31)
C99 4 Gy 4.44
(2.37 to 8.86)
3
(1.66 to 5.92)
0.97
(0.30 to 3.48)
0.44
(0.22 to 0.87)
14.2
(0.16 to 18)
0.49
(0.27 to 0.92)
Cell line AZD-7762 IC50 PF4777 IC50 AZD-6244 IC50 Trametinib IC50 Vemurafenib IC50
LS411 0 Gy 2.69
(1.5 to 6.50)
3.84
(2.91 to 5.08)
11.92
(5.13 to 39.4)
2.03
(0.08 to 25.26)
58.81
(30.19 to 144.8)
LS411 4 Gy 0.41
(0.25 to 0.69)
1.49
(1.06 to 1.83)
6.94
(2.62 to 24.83)
1.81
(0.006 to 48.6)
20.39
(4.63 to 210.7)
Continued
4 Radiosensitisation of colorectal cancer cells
Continued
 
Cell line 5-FU IC50 Vorinostat IC50 PI-103 IC50 Olaparib IC50 Rucaparib IC50
Mitoxantrone
IC50
RKO 0 Gy 0.02
(0.015 to 0.03)
0.47
(0.31 to 0.71)
*148.75 0.09
(0.03 to 0.3)
15.14
(4.37 to 57.2)
RKO 4 Gy 0.005
(0.004 to 0.008)
0.19
(0.15 to 0.25)
4.62
(0.74 to 46.47)
0.03
(0.01 to 0.07)
4.57
(0.99 to 29.93)
VACO5 0 Gy 0.05
(0.03 to 0.11)
1.5
(1.06 to 2.16)
14.81
(7.95 to 29.18)
0.01
(0.007 to 0.017)
9.37
(6.57 to 13.45)
VACO5 4 Gy 0.01
(0.004 to 0.02)
0.28
(0.23 to 0.34)
7.08
(4.28 to 11.86)
0.003
(0.003 to 0.004)
3.86
(2.6 to 5.84)
HT29 0 Gy 0.03
(0.02 to 0.06)
4.08
(2.58 to 6.89)
2.34(1.02 to 5.62) 0.02
(0.01 to 0.04)
13.1
(5.49 to 32.24)
HT29 4 Gy 0.01
(0.003 to 0.03)
1.57
(1.03 to 2.45)
1.87(0.62 to 6.39) 0.01
(0.007 to 0.02)
11.76
(6.68 to 20.96)
OXCO4 0 Gy 2.14
(1.39 to 3.73)
1.54
(1.08 to 2.22)
3.04
(1.76 to 5.35)
*0.15 14.57
(10.14 to 21.19)
OXCO4 4 Gy 0.17
(0.13 to 0.22)
0.76
(0.54 to 1.09)
0.82
(0.33 to 2.4)
*0.06 10.6
(4.09 to 28.44)
CW2 0 Gy 2.16
(1.17 to 5.32)
26.75
(21.9 to 32.78)
1.72
(0.47 to 9.39)
0.46
(0.2 to 1.24)
*53.05
CW2 4 Gy * >2 20.75
(6.06 to 71.96)
* >10 0.18
(0.076 to 0.44)
*49.07
DLD1 0 Gy 0.14
(0.1 to 0.21)
* 15.02 * >20 * >1 *66.41
DLD1 4 Gy 0.02
(0.01 to 0.05)
5.46
(2.36 to 12.91)
* >20 0.08
(0.02 to 0.59)
33.24
(14.01 to 84.84)
CCK81 0 Gy 0.75
(0.43 to 1.42)
* >10 * >20 *>1 * >160
CCK81 4Gy 0.11
(0.08 to 0.17)
* >10 * >20 * >1 * >160
C10 0 Gy 0.12
(0.1 to 0.15)
*10.08 *25.69 0.68
(0.26 to 3.31)
53.16
(30.73 to 99.45)
C10 4 Gy 0.12
(0.08 to 0.2)
* >10 * >20 0.29
(0.13 to 0.74)
48.79
(23.05 to 119.8)
SW403 0 Gy 0.26
(0.18 to 0.37)
0.79
(0.44 to 1.41)
6.45
(3.02 to 15.7)
*2.03 * >80
SW403 4 Gy 0.13
(0.1 to 0.16)
0.37
(0.22 to 0.62)
1.71
(1.08 to 2.76)
* 1.68 * >80
COLO678 0
Gy
* >2 *25.14 1.12
(0.72 to 1.78)
0.006
(0.005 to 0.008)
* >80
COLO678 4
Gy
* >2 *25.39 1.47
(1.07 to 2.04)
0.005
(0.002 to 0.01)
* >80
SW1222 0 Gy 0.07
(0.05 to 0.1)
6.26
(4.02 to 10.64)
3.75
(0.64 to 45.5)
0.23
(0.09 to 0.69)
* >160
SW1222 4 Gy 0.02
(0.02 to 0.02)
1.19
(0.76 to 1.91)
0.61
(0.43 to 0.87)
0.04
(0.02 to 0.07)
39.5
(27.01-57.36)
Continued
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Cell line 5-FU IC50 Vorinostat IC50 PI-103 IC50 Olaparib IC50 Rucaparib IC50 Mitoxantrone IC50
HCA7 0 Gy 0.06
(0.01 to 0.47)
2.37
(1.76 to 3.26)
* >20 0.41
(0.21 to 0.89)
196.8
(178.93 to 231)
HCA7 4 Gy 0.01
(0.00 to 0.14)
0.42
(0.36 to 0.49)
*18.77 0.15
(0.09 to 0.24)
116.7
(64.29 to 256.3)
HT55 0 Gy 0.06
(0.05 to 0.09)
0.97
(0.73 to 1.28)
1.55
(0.28 to 5.02)
0.08
(0.03 to 0.29)
49.39
(15.7 to 169.4)
HT55 4 Gy 0.02
(0.01 to 0.02)
0.37
(0.3 to 0.47)
1.55
(0.41 to 3.33)
0.05
(0.03 to 0.09)
50.77
(22.77 to 132)
C99 0 Gy 0.12
(0.07 to 0.22)
3.75
(1.92 to 8.38)
1.27
(0.32 to 5.5)
0.01
(0.007 to 0.023)
* >160
C99 4 Gy 0.34
(0.07 to 2.32)
1.43
(0.32 to 7.72)
0.38
(0.16 to 1.08)
0.004
(0.002 to 0.007)
* >160
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